![5 Ways to Improve Your LinkedIn Marketing Efforts in 2025 [Infographic]](https://imgproxy.divecdn.com/Hv-m77iIkXSAtB3IEwA3XAuouMwkZApIeDGDnLy5Yhs/g:ce/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9saW5rZWRpbl9zdHJhdGVneV9pbmZvMi5wbmc=.webp "5 Ways to Improve Your LinkedIn Marketing Efforts in 2025 [Infographic]")
BRUSSELS—The European Union blocked Illumina acquisition of cancer-test developer Grail Inc., putting a $7.1 billion merger into jeopardy just days after a U.S. administrative law judge allowed it to go forward.
The bloc’s antitrust regulator said Tuesday the purchase would stifle innovation and reduce choice in an emerging market for early cancer-detection blood tests. The decision could prompt Illumina, a maker of gene-sequencing machines, to shed Grail just over a year after scooping it up.
